Suppr超能文献

生物假体瓣膜破裂:爱德华兹PERIMOUNT P 2900型号测试

Bioprosthetic Valve Fracturing: Testing of Edwards PERIMOUNT Model P 2900.

作者信息

Ruge Hendrik, Alvarez-Covarrubias Hector A, Deutsch Oliver, Alalawi Zahra, Vitanova Keti, Lange Rüdiger

机构信息

Department of Cardiovascular Surgery, German Heart Center, INSURE (Institute for Translational Cardiac Surgery), TUM, Munich, Germany.

German Heart Center Munich, Department of Cardiovascular Surgery, TUM, Munich, Germany.

出版信息

Front Cardiovasc Med. 2022 Jun 2;9:859088. doi: 10.3389/fcvm.2022.859088. eCollection 2022.

Abstract

BACKGROUND

Bioprosthetic valve fracturing (BVF) results in low gradients following valve-in-valve transcatheter aortic valve replacement (ViV-TAVR). For the commonly used Edwards PERIMOUNT valve data from bench-testing are lacking to provide technical specifications for successful BVF during ViV-TAVR.

METHODS

Using four Perimount 19- and 21-mm valves, high-pressure balloon valvuloplasty with the True Dilatation Balloon Valvuloplasty Catheter and Atlas Gold PTA Dilatation Catheter was performed to analyze balloon-oversizing and pressure-thresholds to successfully achieve BVF.

RESULTS

High-pressure balloons one millimeter larger than the labeled valve size and pressure rates of 20 atm (for Perimount 19-mm) and > 22 atm (for Perimount 21-mm) were required to achieve BVF. Caliper measurements demonstrated 2.5 mm (Perimount 19-mm) and 1.5 mm (Perimount 21-mm) enlarged inner prosthetic diameters after BVF. The Atlas TM Gold PTA Dilatation Catheter achieved BVF with the Perimount 21-mm, whereas the True TM Dilatation Balloon Valvuloplasty Catheter failed in the Perimount 21-mm either for balloon-rupture or pinhole-defect.

CONCLUSION

Both 19-mm and 21-mm Perimount P 2900 are amendable to BVF, thereby increasing the inner prosthetic diameter. High-pressure balloons 1 mm larger than the labeled valves are essential for this purpose, and the Atlas Gold PTA Dilatation Catheter alone should ensure success in the 21-mm prosthetics.

摘要

背景

生物瓣膜破裂(BVF)会导致经导管主动脉瓣置换术(ViV-TAVR)后梯度降低。对于常用的爱德华兹PERIMOUNT瓣膜,缺乏台架试验数据来提供ViV-TAVR期间成功进行BVF的技术规范。

方法

使用四个19毫米和21毫米的Perimount瓣膜,采用True Dilatation球囊瓣膜成形术导管和Atlas Gold PTA扩张导管进行高压球囊瓣膜成形术,以分析球囊超尺寸和压力阈值,从而成功实现BVF。

结果

需要比标记瓣膜尺寸大1毫米的高压球囊以及20个大气压(对于19毫米的Perimount瓣膜)和大于22个大气压(对于21毫米的Perimount瓣膜)的压力率才能实现BVF。卡尺测量显示,BVF后人工瓣膜内径扩大了2.5毫米(19毫米的Perimount瓣膜)和1.5毫米(21毫米的Perimount瓣膜)。Atlas TM Gold PTA扩张导管成功实现了21毫米Perimount瓣膜的BVF,而True TM扩张球囊瓣膜成形术导管在21毫米的Perimount瓣膜上因球囊破裂或针孔缺陷而失败。

结论

19毫米和21毫米的Perimount P 2900瓣膜均可进行BVF,从而增加人工瓣膜内径。为此,比标记瓣膜大1毫米的高压球囊必不可少,仅Atlas Gold PTA扩张导管应能确保21毫米人工瓣膜手术成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9626/9238356/2237f8577f4d/fcvm-09-859088-g0001.jpg

相似文献

1
Bioprosthetic Valve Fracturing: Testing of Edwards PERIMOUNT Model P 2900.
Front Cardiovasc Med. 2022 Jun 2;9:859088. doi: 10.3389/fcvm.2022.859088. eCollection 2022.
2
Frequency of Bioprosthetic Valve Fracturing Utilization in an All-Comers Valve-in-Valve TAVR Cohort.
Front Cardiovasc Med. 2021 Jul 1;8:653871. doi: 10.3389/fcvm.2021.653871. eCollection 2021.
3
Bioprosthetic Valve Fracture Improves the Hemodynamic Results of Valve-in-Valve Transcatheter Aortic Valve Replacement.
Circ Cardiovasc Interv. 2017 Jul;10(7). doi: 10.1161/CIRCINTERVENTIONS.117.005216.
4
Bioprosthetic valve fracture: Technical insights from a multicenter study.
J Thorac Cardiovasc Surg. 2019 Nov;158(5):1317-1328.e1. doi: 10.1016/j.jtcvs.2019.01.073. Epub 2019 Jan 31.
6
Bioprosthetic valve fracture during valve-in-valve transcatheter aortic valve replacement.
Proc (Bayl Univ Med Cent). 2020 Mar 6;33(3):317-321. doi: 10.1080/08998280.2020.1732267. eCollection 2020 Jul.
7
New Insights and Perspective on Bioprosthetic Valve Fracture From Bench Testing and Computed Tomography Analysis.
Struct Heart. 2024 Feb 5;8(3):100276. doi: 10.1016/j.shj.2023.100276. eCollection 2024 May.
9
Bioprosthetic Valve Fracture During Valve-in-valve TAVR: Bench to Bedside.
Interv Cardiol. 2018 Jan;13(1):20-26. doi: 10.15420/icr.2017:29:1.

引用本文的文献

本文引用的文献

1
Frequency of Bioprosthetic Valve Fracturing Utilization in an All-Comers Valve-in-Valve TAVR Cohort.
Front Cardiovasc Med. 2021 Jul 1;8:653871. doi: 10.3389/fcvm.2021.653871. eCollection 2021.
3
Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study.
Catheter Cardiovasc Interv. 2021 Oct;98(4):756-764. doi: 10.1002/ccd.29755. Epub 2021 May 15.
4
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves.
Eur Heart J. 2020 Aug 1;41(29):2731-2742. doi: 10.1093/eurheartj/ehaa544.
6
Bioprosthetic valve fracture: Technical insights from a multicenter study.
J Thorac Cardiovasc Surg. 2019 Nov;158(5):1317-1328.e1. doi: 10.1016/j.jtcvs.2019.01.073. Epub 2019 Jan 31.
7
Bioprosthetic Valve Fracture Improves the Hemodynamic Results of Valve-in-Valve Transcatheter Aortic Valve Replacement.
Circ Cardiovasc Interv. 2017 Jul;10(7). doi: 10.1161/CIRCINTERVENTIONS.117.005216.
8
Fracturing mechanics before valve-in-valve therapy of small aortic bioprosthetic heart valves.
EuroIntervention. 2017 Oct 13;13(9):e1026-e1031. doi: 10.4244/EIJ-D-17-00245.
9
Bioprosthetic Valve Fracture to Facilitate Transcatheter Valve-in-Valve Implantation.
Ann Thorac Surg. 2017 Nov;104(5):1501-1508. doi: 10.1016/j.athoracsur.2017.04.007. Epub 2017 Jun 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验